Poly Medicure (POLYMED) Stock Overview
Engages in the manufacture and sale of medical devices in India and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 3/6 |
| Past Performance | 2/6 |
| Financial Health | 6/6 |
| Dividends | 2/6 |
Rewards
Risk Analysis
No risks detected for POLYMED from our risk checks.
POLYMED Community Fair Values
Create NarrativeSee what 10 others think this stock is worth. Follow their fair value or set your own to get alerts.
Poly Medicure Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹1,510.90 |
| 52 Week High | ₹2,316.60 |
| 52 Week Low | ₹1,182.00 |
| Beta | 0.055 |
| 1 Month Change | 0.80% |
| 3 Month Change | 21.71% |
| 1 Year Change | -31.19% |
| 3 Year Change | 32.12% |
| 5 Year Change | 65.99% |
| Change since IPO | 4,107.90% |
Recent News & Updates
Here's Why We Think Poly Medicure (NSE:POLYMED) Is Well Worth Watching
The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...Poly Medicure Limited Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now
Poly Medicure Limited ( NSE:POLYMED ) last week reported its latest quarterly results, which makes it a good time for...Recent updates
Shareholder Returns
| POLYMED | IN Medical Equipment | IN Market | |
|---|---|---|---|
| 7D | 9.3% | 7.5% | 2.8% |
| 1Y | -31.2% | -35.7% | -1.5% |
Return vs Industry: POLYMED exceeded the Indian Medical Equipment industry which returned -35.3% over the past year.
Return vs Market: POLYMED underperformed the Indian Market which returned -2% over the past year.
Price Volatility
| POLYMED volatility | |
|---|---|
| POLYMED Average Weekly Movement | 7.3% |
| Medical Equipment Industry Average Movement | 7.6% |
| Market Average Movement | 7.1% |
| 10% most volatile stocks in IN Market | 10.2% |
| 10% least volatile stocks in IN Market | 4.7% |
Stable Share Price: POLYMED has not had significant price volatility in the past 3 months compared to the Indian market.
Volatility Over Time: POLYMED's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1995 | 3,082 | Himanshu Baid | www.polymedicure.com |
Poly Medicure Limited engages in the manufacture and sale of medical devices in India and internationally. The company offers infusion therapy products, such as I.V Infusion set, extension lines, needle free connector, I.V flow regulator extension set, burette set, three way stop cock, vial access spike, transfer spike, orburator, polyflush, maifolds, polyswab, and arterial blood collection; critical care products, including vial access spikes, arterial cannula, mini mid lines over the wire, extension line, enteral connector, central venous catheters, and huber needle; dialysis and renal care products, comprising peritoneal dialysis set, haemocent, standard and safety fistula needle, dialyzer, bloodlines and dialysis system. It also provides cardiology products PTFE wire, inflation device, Y-connector, manifold, introducer, IV Cannula, hydrophilic wire, guiding catheter, drug eluting stent, PTCA dilation catheter, diagnostic catheter, and electrocardiograph electrodes; vaccular access products; oncology products; diagnostics products, such as blood collection tubes, safety blood collection set, blood collection needles, and standard needle holder.
Poly Medicure Limited Fundamentals Summary
| POLYMED fundamental statistics | |
|---|---|
| Market cap | ₹153.30b |
| Earnings (TTM) | ₹3.22b |
| Revenue (TTM) | ₹18.75b |
Is POLYMED overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| POLYMED income statement (TTM) | |
|---|---|
| Revenue | ₹18.75b |
| Cost of Revenue | ₹5.97b |
| Gross Profit | ₹12.78b |
| Other Expenses | ₹9.56b |
| Earnings | ₹3.22b |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | 31.78 |
| Gross Margin | 68.17% |
| Net Profit Margin | 17.18% |
| Debt/Equity Ratio | 10.8% |
How did POLYMED perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/06/15 11:15 |
| End of Day Share Price | 2026/06/15 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2026/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Poly Medicure Limited is covered by 9 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Karan Khanna | Ambit Capital |
| Rashmi Sancheti Shetty | Dolat Capital Market Pvt. Ltd. |
| Candice Pereira | Dolat Capital Market Pvt. Ltd. |